In breast cancer, a preclinical study using breast cancer cell lines showed that PARP inhibition up-regulated PD-L1 expression, and that combination treatment with PARP inhibition and anti-PD-L1 therapy was significantly more efficacious than either treatment alone [102]. This evidence concerns the gene PARP1 and breast carcinoma.